{"entity":{"id":"nct04162210","kind":"trial","name":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple","aka":["DREAMM 3"],"tldr":"A phase 3 trial of Belantamab mafodotin in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.","summary":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04162210 by GlaxoSmithKline, with 325 participants enrolled, started 2020-04-02 and due to reach its primary completion in 2022-09-12. Interventions recorded: Belantamab mafodotin, Pom/dex (Pomalidomide plus low dose Dexamethasone). Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2023; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT04162210","url":"https://clinicaltrials.gov/study/NCT04162210"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma","myeloma-relapsed-refractory"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["belantamab-mafodotin"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04162210","phase":"3","setting":"A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)","sponsor":"GlaxoSmithKline","started":"2020-04-02","startedType":"actual","yearReported":2023,"enrolled":325,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-Free Survival (PFS) Based on Investigator-Assessed Response as Per International Myeloma Working Group (IMWG)","primary":true,"unit":"months","arms":[{"name":"Belantamab Mafodotin","n":218,"value":11.2,"note":"95% CI 6.4 to 14.5; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication"},{"name":"Pomalidomide Plus Dexamethasone","n":107,"value":7,"note":"95% CI 4.6 to 10.6"}],"hr":1.03,"ci":[0.72,1.47],"p":"0.558","source":"https://clinicaltrials.gov/study/NCT04162210?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"Belantamab Mafodotin","n":218,"value":24,"note":"95% CI 19.4 to 33.2; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication"},{"name":"Pomalidomide Plus Dexamethasone","n":107,"value":22.9,"note":"95% CI 16.0 to 29.3"}],"hr":0.98,"ci":[0.73,1.3],"p":"0.440","source":"https://clinicaltrials.gov/study/NCT04162210?tab=results"},{"endpoint":"Overall Response Rate (ORR)","unit":"%","arms":[{"name":"Belantamab Mafodotin","n":218,"value":41,"note":"95% CI 34.7 to 48.1; Figures from the ClinicalTrials.gov results section (first posted 2023-10-06), not from a publication"},{"name":"Pomalidomide Plus Dexamethasone","n":107,"value":36,"note":"95% CI 26.5 to 45.4"}],"source":"https://clinicaltrials.gov/study/NCT04162210?tab=results"}]},"route":"/trials/nct04162210/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"myeloma-relapsed-refractory","kind":"cancer","name":"Relapsed or refractory multiple myeloma","route":"/cancers/myeloma-relapsed-refractory/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"belantamab-mafodotin","kind":"drug","name":"Belantamab mafodotin","route":"/drugs/belantamab-mafodotin/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}]}}